Sign inCreate account

Report workspace

Add to folder
NCT05257460COMPLETEDanonymous

Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions. A Double-blinded, Single Centre, Randomised, Two-period, Crossover Extension Phase to Evaluate Home Use of Closed-loop Applying Ultra-rapid Insulin Lispro Versus Standard Insulin Lispro (Phase 4).

Sponsor

Source record

University of Cambridge

Phase

Source record

Phase 4

Modality

AI-normalized

medical device

Target

AI-normalized

Closed-loop insulin delivery system utilizing ultra-rapid insulin lispro (Lyumjev) versus standard insulin lispro (Humalog) for glucose control in adults with Type 1 Diabetes.

Indication / condition

AI-normalized

Type 1 Diabetes

Intervention

Source record

Hybrid closed-loop using ultra-rapid insulin lispro, Hybrid closed-loop using standard insulin lispro

Source & freshness

Source record

NCT ID

NCT05257460

Original source

ClinicalTrials.gov

Source last updated

May 09, 2023

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05257460

Title

Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions. A Double-blinded, Single Centre, Randomised, Two-period, Crossover Extension Phase to Evaluate Home Use of Closed-loop Applying Ultra-rapid Insulin Lispro Versus Standard Insulin Lispro (Phase 4).

Sponsor

University of Cambridge

Status

COMPLETED

Phase

Phase 4

Condition raw

Type 1 Diabetes

Condition normalized

Type 1 Diabetes

Modality raw

medical device

Modality normalized

medical device

Target raw

Closed-loop insulin delivery system utilizing ultra-rapid insulin lispro (Lyumjev) versus standard insulin lispro (Humalog) for glucose control in adults with Type 1 Diabetes.

Target normalized

Closed-loop insulin delivery system utilizing ultra-rapid insulin lispro (Lyumjev) versus standard insulin lispro (Humalog) for glucose control in adults with Type 1 Diabetes.

Interventions

Hybrid closed-loop using ultra-rapid insulin lispro, Hybrid closed-loop using standard insulin lispro

Public preview

Source record

The trial, sponsored by the University of Cambridge, aims to evaluate the efficacy and safety of a closed-loop insulin delivery system using ultra-rapid insulin lispro compared to standard insulin lispro in adults with Type 1 Diabetes. If successful, this study could enhance the competitive positioning of ultra-rapid insulin lispro in the diabetes management market, which is increasingly focused on advanced insulin delivery systems and personalized treatment approaches. The findings may also influence market dynamics by potentially increasing the adoption of hybrid closed-loop systems, thereby impacting existing players in the insulin and diabetes technology sectors. Companies involved in diabetes management technologies should monitor these results closely for implications on product development and market strategies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions. A Double-blinded, Single Centre, Randomised, Two-period, Crossover Extension Phase to Evaluate Home Use of Closed-loop Applying Ultra-rapid Insulin Lispro Versus Standard Insulin Lispro (Phase 4).

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT05257460

Status

COMPLETED

Phase

Phase 4

Sponsor

University of Cambridge

Executive brief

Investment-Ready Snapshot

The trial, sponsored by the University of Cambridge, aims to evaluate the efficacy and safety of a closed-loop insulin delivery system using ultra-rapid insulin lispro compared to standard insulin lispro in adults with Type 1 Diabetes. If successful, this study could enhance the competitive positioning of ultra-rapid insulin lispro in the diabetes management market, which is increasingly focused on advanced insulin delivery systems and personalized treatment approaches. The findings may also influence market dynamics by potentially increasing the adoption of hybrid closed-loop systems, thereby impacting existing players in the insulin and diabetes technology sectors. Companies involved in diabetes management technologies should monitor these results closely for implications on product development and market strategies.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 09, 2023
Internal syncJun 13, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05257460

Indication

Type 1 Diabetes

Modality

medical device

Target

Closed-loop insulin delivery system utilizing ultra-rapid insulin lispro (Lyumjev) versus standard insulin lispro (Humalog) for glucose control in adults with Type 1 Diabetes.

Intervention

Hybrid closed-loop using ultra-rapid insulin lispro, Hybrid closed-loop using standard insulin lispro

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.